Nasdaq: RNA

Atrium Therapeutics, Inc. (RNA)

Atrium Therapeutics, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker RNA. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
RNA
Exchange
Nasdaq
SEC CIK
2093101
Official filings
SEC EDGAR

Research RNA

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Atrium Therapeutics, Inc.'s stock ticker?

Atrium Therapeutics, Inc. trades under the ticker symbol RNA on Nasdaq. Its SEC Central Index Key (CIK) is 2093101.

Where can I read Atrium Therapeutics, Inc.'s SEC filings?

The RNA SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Atrium Therapeutics, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze RNA's financial statements?

The RNA Financials page shows Atrium Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does RNA compare with its peers and the market?

The RNA Peer Comparison page lines Atrium Therapeutics, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.